Invitrogen™ Anthrax Lethal Factor Synthetic Peptide

Catalog No.	Quantity
PEP0212	50 μg

Catalog No. PEP0212 Supplier Invitrogen™ Supplier No. PEP0212

Description

Synthetic Peptide

Anthrax Lethal Factor Synthetic Peptide, PEP-0212, from Invitrogen.

Anthrax infection is initiated by the inhalation, ingestion, or cutaneous contact with Bacillus anthracis endospores. B. anthracis produces three polypeptides that comprise the anthrax toxin: protective antigen (PA), lethal factor (LF), and edema factor (EF). PA binds to two related proteins on the cell surface; these are termed tumor epithelial marker 8 (TEM8)/anthrax toxin receptor (ATR) and capillary morphogenesis protein 2 (CMG2), although it is still unclear which is physiologically relevant. Following PA binding to its receptor, PA is cleaved into two fragments by a furin-like protease. The bound fragment binds both LF and EF; the resulting complex is then endocytosed which allows the translocation of LF and EF into the cytoplasm. LF is the primary toxin of anthrax and functions as a highly specific protease that cleaves members of the mitogen-activated protein kinase kinase (MAPKK) family near their amino terminus, interfering with MAPK signaling and inducing apoptosis.

Specifications

• Species: Bacteria
• Purification Method: purified
• Common Name: Anthrax Lethal Factor
• Concentration: 200 μg/mL
• Content And Storage: -20°C
• Description: Synthetic Peptide
• Format: Liquid
• Formulation: PBS with 0.1% BSA and 0.02% sodium azide; pH 7.2
• For Use With (Application): Blocking Assay, Control
• Lyophilized: No
• Preservative: 0.02% sodium azide
• Product Type: Peptide
• Quantity: 50 μg
• Regulatory Status: RUO - research use only
• Storage Buffer: PBS